Celyad to Present at the Deutsche Bank 42nd Annual Health Care Conference
May 03, 2017 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, May 03, 2017 (GLOBE NEWSWIRE) -- Celyad (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell-based therapies, today...
Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents
May 02, 2017 02:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, May 02, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of cell therapies, today...
Celyad initiates second dose escalation in THINK trial in first US patient
April 28, 2017 02:00 ET
|
Celyad SA
Initiation of the THINK trial in the US at Roswell Park Cancer InstituteDosing of the first patient of the second dose (1x109) in solid tumor armFavorable safety profile reported on all patients...
Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017
March 23, 2017 02:00 ET
|
Celyad SA
First clinical trial of CAR-T NKR-2 cell therapy completed with encouraging safety profile and unexpected signals of clinical activity at the low doses tested. Strong cash position expected to fund...
USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells
March 16, 2017 02:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, March 16, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell-based...
Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA
March 08, 2017 01:00 ET
|
Celyad SA
IND (Investigational New Drug) approval triggers the initiation of the THINK trial in the U.S. Rosewell Park (NY) and University of Pittsburgh Medical Center – UPMC (PA) approved and ready to enroll...
Celyad to Present at Cowen and Company 37th Annual Health Care Conference
March 01, 2017 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, March 01, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell-based...
Celyad Registers First Hematological Patient in CAR-T NKR-2 THINK Trial
February 16, 2017 01:00 ET
|
Celyad SA
Opening of the hematological arm of the CAR-T NKR-2 THINK trial with first Multiple Myeloma patient.No toxic events reported in patients enrolled in the solid arm of the study so far. ...
Celyad Announces Registration of the First Pancreatic Cancer Patient in its CAR-T NKR-2THINK Trial in Belgium
January 11, 2017 13:58 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Jan. 11, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris: CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell-based therapies,...
Celyad Announces USPTO Decision to Uphold US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells
January 09, 2017 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell-based...